2157 — Lepu Biopharma Co Cashflow Statement
0.000.00%
- HK$7.25bn
- HK$7.63bn
- CNY367.79m
Annual cashflow statement for Lepu Biopharma Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | — |
Source: | PROSPECTUS | ARS | ARS | ARS | |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | fx Preliminary |
Net Income/Starting Line | -613 | -1,029 | -699 | -30.3 | — |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 170 | 198 | 86.4 | -343 | — |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -63.7 | 114 | 36.7 | 19.7 | — |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Accounts Payable | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -423 | -622 | -481 | -251 | — |
Capital Expenditures | -311 | -220 | -115 | -41.2 | — |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -439 | 216 | 40.8 | 59.5 | — |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Sale of Intangible Assets | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -750 | -3.89 | -74.7 | 18.3 | — |
Financing Cash Flow Items | 0.805 | -11.1 | -56 | -30.6 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1,387 | 380 | 1,032 | -11 | — |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 214 | -248 | 514 | -243 | — |